Multispan and Promega streamlining GPCR screening
Promega and San Francisco area-based Multispan have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening by combining Multispan GPCR cell lines and Promega bioluminescent technologies.
MADISON, Wis.—Promega and San Francisco area-based Multispan have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening by combining Multispan GPCR cell lines and Promega bioluminescent technologies. The first tools will support cell lines and cAMP-Glo Assay for quantification of signal. Additional tools will be developed for cell-based assay detection. This combination of validated biologic components and a sensitive and dynamic luminescence assay detection technology for high-throughput screening reportedly will provide increased speed and efficiency in GPCR drug screening."Pre-optimized protocols will reduce assay development times, from months to days, helping deliver better GPCR targeted drugs faster," according to John Watson, marketing director of pharma/biotech at Promega. "Our suite of assay tools can be combined with Multispan's validated GPCR cell lines to provide turnkey solutions for drug discovery scientists."
